Jarred Burkart

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Nieves Martínez Chanzá, Wanling Xie, Mehmet Asım Bilen et al. · The Lancet Oncology · 2019 · 175 citations

Medicine, Oncology, Pharmacology +11

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

Mingjia Li, Daniel Spakowicz, Jarred Burkart et al. · Journal of Cancer Research and Clinical Oncology · 2019 · 117 citations · Full text

Medicine, Immunology, Oncology +14

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H. Owen et al. · Cancer Immunology Immunotherapy · 2020 · 97 citations · Full text

Medicine, Immunology, Oncology +15

Atonal Homolog 1 Is Required for Growth and Differentiation Effects of Notch/γ-Secretase Inhibitors on Normal and Cancerous Intestinal Epithelial Cells

Avedis Kazanjian, Taeko K. Noah, Douglas Brown et al. · Gastroenterology · 2010 · 90 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

Daniel Spakowicz, Rebecca Hoyd, Mitchell Muniak et al. · BMC Cancer · 2020 · 61 citations · Full text

Medicine, Oncology, Pharmacology +14